r slide # 1 valganciclovir for the treatment of cmv retinitis
TRANSCRIPT
![Page 1: R Slide # 1 VALGANCICLOVIR FOR THE TREATMENT OF CMV RETINITIS](https://reader035.vdocument.in/reader035/viewer/2022081421/5697bfea1a28abf838cb7218/html5/thumbnails/1.jpg)
Slide # 1
VALGANCICLOVIR FOR THE
TREATMENT OF CMV RETINITIS
![Page 2: R Slide # 1 VALGANCICLOVIR FOR THE TREATMENT OF CMV RETINITIS](https://reader035.vdocument.in/reader035/viewer/2022081421/5697bfea1a28abf838cb7218/html5/thumbnails/2.jpg)
Slide # 2
GOAL
Roche seeks approval recommendation:
Valganciclovir (Val-GCV) is indicated for the treatment of CMV retinitis in patients with AIDS
![Page 3: R Slide # 1 VALGANCICLOVIR FOR THE TREATMENT OF CMV RETINITIS](https://reader035.vdocument.in/reader035/viewer/2022081421/5697bfea1a28abf838cb7218/html5/thumbnails/3.jpg)
Slide # 3
AGENDA AND PRESENTERS
DEVELOPMENT PROGRAM & STUDY RESULTS- Mary Jean Stempien, MD, MS
INTRODUCTION- Mary Jean Stempien, MD, MS Director, Medical Research, Roche
CLINICAL BACKGROUND- Daniel F. Martin, MD Associate Professor of Ophthalmology Emory University School of Medicine
![Page 4: R Slide # 1 VALGANCICLOVIR FOR THE TREATMENT OF CMV RETINITIS](https://reader035.vdocument.in/reader035/viewer/2022081421/5697bfea1a28abf838cb7218/html5/thumbnails/4.jpg)
Slide # 4
EXPERTS
Gary Koch, Ph.D.
Professor of BiostatisticsUniversity of North Carolina, Chapel Hill
Nancy C. Sambol, Pharm.D.
Associate Clinical Professor Department of Biopharmaceutical SciencesUniversity of California, San Francisco
![Page 5: R Slide # 1 VALGANCICLOVIR FOR THE TREATMENT OF CMV RETINITIS](https://reader035.vdocument.in/reader035/viewer/2022081421/5697bfea1a28abf838cb7218/html5/thumbnails/5.jpg)
Slide # 5
CLINICAL BACKGROUND
![Page 6: R Slide # 1 VALGANCICLOVIR FOR THE TREATMENT OF CMV RETINITIS](https://reader035.vdocument.in/reader035/viewer/2022081421/5697bfea1a28abf838cb7218/html5/thumbnails/6.jpg)
Slide # 6
CLINICAL BACKGROUND
Daniel F. Martin, M.D.Associate Professor of OphthalmologyEmory University School of Medicine
Clinical Features of CMV Retinitis
Impact of HAART
Treatment Options
![Page 7: R Slide # 1 VALGANCICLOVIR FOR THE TREATMENT OF CMV RETINITIS](https://reader035.vdocument.in/reader035/viewer/2022081421/5697bfea1a28abf838cb7218/html5/thumbnails/7.jpg)
Slide # 7
![Page 8: R Slide # 1 VALGANCICLOVIR FOR THE TREATMENT OF CMV RETINITIS](https://reader035.vdocument.in/reader035/viewer/2022081421/5697bfea1a28abf838cb7218/html5/thumbnails/8.jpg)
Slide # 8
![Page 9: R Slide # 1 VALGANCICLOVIR FOR THE TREATMENT OF CMV RETINITIS](https://reader035.vdocument.in/reader035/viewer/2022081421/5697bfea1a28abf838cb7218/html5/thumbnails/9.jpg)
Slide # 9
![Page 10: R Slide # 1 VALGANCICLOVIR FOR THE TREATMENT OF CMV RETINITIS](https://reader035.vdocument.in/reader035/viewer/2022081421/5697bfea1a28abf838cb7218/html5/thumbnails/10.jpg)
Slide # 10